Human epidermal growth factor receptor 2 (HER2) status identification is established by immunohistochemistry and in situ hybridisation (ISH). Silver in situ hybridisation (SISH) is an alternative technique to the fluorescence in situ hybridization (FISH). Both methods are recommended by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2013 guidelines. The primary aim of this analysis is to evaluate the economical and organizational impact by adopting FISH or SISH test for HER2 testing
Abstract In August 2006, the Australian government approved subsidized trastuzumab therapy for human...
Our purposes were to perform a robust assessment of a new HER2 chromogenic in situ hybridization te...
ASCO and the College of American Pathologists (ASCO-CAP) recently recommended further changes to the...
Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to iden...
Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastu...
PubMed ID: 29146056HER2 amplification has been demonstrated in 15–25% of invasive breast carcinomas ...
HER2 amplification has been demonstrated in 15-25% of invasive breast carcinomas and can be assessed...
Introduction: HER2 gene amplification or overexpression occurs in 15% to 25% of breast cancers and h...
Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to...
The human epidermal growth factor receptor-2 (HER2) protein has been associated with breast cancer p...
Accurate assessment of human epidermal growth factor receptor 2 (HER-2) is crucial in selecting pati...
Silver-enhanced in-situ hybridization (SISH) is an emerging tool for the determination of the Her-2/...
INTRODUCTION HER2 status assessment became a mandatory test assay in breast cancer, giving prognost...
In August 2006, the Australian government approved subsidized trastuzumab therapy for human epiderma...
HER2 gene amplification was explored using the silver stain hybridization in situ (SISH) technique i...
Abstract In August 2006, the Australian government approved subsidized trastuzumab therapy for human...
Our purposes were to perform a robust assessment of a new HER2 chromogenic in situ hybridization te...
ASCO and the College of American Pathologists (ASCO-CAP) recently recommended further changes to the...
Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to iden...
Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastu...
PubMed ID: 29146056HER2 amplification has been demonstrated in 15–25% of invasive breast carcinomas ...
HER2 amplification has been demonstrated in 15-25% of invasive breast carcinomas and can be assessed...
Introduction: HER2 gene amplification or overexpression occurs in 15% to 25% of breast cancers and h...
Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to...
The human epidermal growth factor receptor-2 (HER2) protein has been associated with breast cancer p...
Accurate assessment of human epidermal growth factor receptor 2 (HER-2) is crucial in selecting pati...
Silver-enhanced in-situ hybridization (SISH) is an emerging tool for the determination of the Her-2/...
INTRODUCTION HER2 status assessment became a mandatory test assay in breast cancer, giving prognost...
In August 2006, the Australian government approved subsidized trastuzumab therapy for human epiderma...
HER2 gene amplification was explored using the silver stain hybridization in situ (SISH) technique i...
Abstract In August 2006, the Australian government approved subsidized trastuzumab therapy for human...
Our purposes were to perform a robust assessment of a new HER2 chromogenic in situ hybridization te...
ASCO and the College of American Pathologists (ASCO-CAP) recently recommended further changes to the...